文献速递痛风与晶体性关节病

双向孟德尔随机化揭示胰岛素抵抗与高尿酸血症及痛风的因果关系

Assessing the Causal Relationships Between Insulin Resistance and Hyperuricemia and Gout Using Bidirectional Mendelian Randomization.
PubMed 文献 · Arthritis Rheumatol · 2021-09-26

本研究采用双向孟德尔随机化分析,利用全基因组关联数据(血清尿酸n=288,649,痛风n=763,813,空腹胰岛素n=153,525)及UK Biobank个体数据(n=360,453)进行两样本和单样本MR。结果发现基因决定的空腹胰岛素浓度与血清尿酸水平正相关(每log单位增加0.37 mg/dl,95%CI 0.15-0.58,P=0.001),而基因决定的尿酸水平与空腹胰岛素无关;痛风风险结果与尿酸一致。结论提示高胰岛素血症导致高尿酸血症,而非反之。

要点

  • 基因决定的空腹胰岛素升高与血清尿酸升高存在正向因果关联。
  • 基因决定的血清尿酸升高不引起空腹胰岛素升高,因果方向为单向。
  • 降低胰岛素抵抗可能降低尿酸水平和痛风风险,而降尿酸治疗未必改善胰岛素抵抗。

核心结论

  • 高胰岛素血症导致高尿酸血症,而非高尿酸血症导致高胰岛素血症。

研究设计与样本

  • 采用双向两样本孟德尔随机化分析,使用全基因组关联数据:血清尿酸n=288,649,痛风风险n=763,813,空腹胰岛素n=153,525。
  • 利用UK Biobank中360,453名欧洲 ancestry 个体的电子病历链接数据进行单样本孟德尔随机化重复分析。

主要发现

  • 基因决定的血清尿酸水平(多基因评分或强效单个位点)与空腹胰岛素浓度无关。
  • 基因决定的空腹胰岛素浓度与血清尿酸水平正相关:每log单位空腹胰岛素增加,血清尿酸升高0.37 mg/dl(95%CI 0.15-0.58;P=0.001)。
  • 该关联在离群值校正后(β=0.56 mg/dl,95%CI 0.45-0.67)和调整BMI的多变量MR中(β=0.69 mg/dl,95%CI 0.53-0.85)持续存在(两者P<0.001)。
  • UK Biobank中空腹胰岛素多基因评分与血清尿酸水平正相关(P<0.001)。
  • 痛风风险的双向结果与血清尿酸水平一致。

关键数值与推荐

  • 空腹胰岛素每log单位增加对应血清尿酸升高0.37 mg/dl(95%CI 0.15-0.58;P=0.001)。
  • 离群值校正后β=0.56 mg/dl(95%CI 0.45-0.67)。
  • 调整BMI的多变量MR中β=0.69 mg/dl(95%CI 0.53-0.85)(P<0.001)。

临床怎么用

  • 改善胰岛素抵抗可能作为降低血清尿酸水平和痛风风险的策略。
  • 降低血清尿酸(如别嘌醇治疗)不太可能减轻胰岛素抵抗及其心血管代谢后遗症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Hyperuricemia is closely associated with insulin resistance syndrome (and its many cardiometabolic sequelae); however, whether they are causally related has long been debated. We undertook this study to investigate the potential causal nature and direction between insulin resistance and hyperuricemia, along with gout, by using bidirectional Mendelian randomization (MR) analyses. METHODS: We used genome-wide association data (n = 288,649 for serum urate [SU] concentration; n = 763,813 for gout risk; n = 153,525 for fasting insulin) to select genetic instruments for 2-sample MR analyses, using multiple MR methods to address potential pleiotropic associations. We then used individual-level, electronic medical record-linked data from the UK Biobank (n = 360,453 persons of European ancestry) to replicate our analyses via single-sample MR analysis. RESULTS: Genetically determined SU levels, whether inferred from a polygenic score or strong individual loci, were not associated with fasting insulin concentrations. In contrast, genetically determined fasting insulin concentrations were positively associated with SU levels (0.37 mg/dl per log-unit increase in fasting insulin [95% confidence interval (95% CI) 0.15, 0.58]; P = 0.001). This persisted in outlier-corrected (β = 0.56 mg/dl [95% CI 0.45, 0.67]) and multivariable MR analyses adjusted for BMI (β = 0.69 mg/dl [95% CI 0.53, 0.85]) (P < 0.001 for both). Polygenic scores for fasting insulin were also positively associated with SU level among individuals in the UK Biobank (P < 0.001). Findings for gout risk were bidirectionally consistent with those for SU level. CONCLUSION: These findings provide evidence to clarify core questions about the close association between hyperuricemia and insulin resistance syndrome: hyperinsulinemia leads to hyperuricemia but not the other way around. Reducing insulin resistance could lower the SU level and gout risk, whereas lowering the SU level (e.g., allopurinol treatment) is unlikely to mitigate insulin resistance and its cardiometabolic sequelae.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. McCormick N, O'Connor MJ, Yokose C, et al. Assessing the Causal Relationships Between Insulin Resistance and Hyperuricemia and Gout Using Bidirectional Mendelian Randomization. Arthritis Rheumatol. 2021. PMID: 33982892. doi:10.1002/art.41779

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。